The aim of this study was to compare the incidence of technical complications of epidural catheters with subcutaneous injection ports to percutaneous epidural catheters without ports, fixed only by adhesive dressing. We reviewed 149 patients who received 250 epidural catheters for treatment of cancer pain during a 3'h-yr period from January 1,1989, to June 30,1992. Of the 250 catheters, 52 were provided with subcutaneous injection ports and 198 were percutaneous catheters. Of the 198 percutaneous catheters, 41 were tunneled for a short distance; the remainder entered the skin at the dorsal midline. In the percutaneous group 21% of the catheters became dislodged. In the injection port group, there were no catheter dislodgements. The overall incidence of infections was similar in both groups (13.6% ). When we indexed the infection rate to catheter-days, the number of infections per 1000 catheter-days in the injection port group was half that of the percutaneous group (2.86 infections versus 5.97 for percutaneous catheters). No injection port became infected during the first 70 days of treatment, whereas in the percutaneous group infections occurred as early as the first week. Within the percutaneous group the complication rate in the tunneled epidural catheters was as high as in the nontunneled. We conclude that injection ports reduce the complication rate of epidural catheters, particularly catheter dislodgement and early infections.
(Anesth Analg 1994;78:94-100) ver since Behar et al.
(1) first reported the use of epidural morphine for the treatment of cancer E pain, anesthesiologists have been looking for a means to overcome the technical problems that can arise during chronic treatment with epidural opioids. These complications include catheter dislodgement, infection, pain on injection, leakage, and occlusion. One option is to tunnel the catheter to the flank or the anterior abdominal wall (2-6). A second option is the implantation of a subcutaneous injection port located on the patient's anterior chest wall (7) (8) (9) (10) (11) (12) (13) (14) (15) . Many reviews of epidural treatment of cancer pain have reported technical complications (Table 1) . Most, however, did not distinguish between different types of catheters.
The aim of this study was to analyze retrospectively the technical complications of epidural catheters, with or without subcutaneous injection ports, when used for treatment of cancer pain.
from January 1, 1989, to June 30, 1992. We did not include the 19 intrathecal catheters inserted during this period. We deliberately considered catheters rather than patients, because some patients had several catheters.
All epidural catheters were inserted in the operating room under aseptic conditions. Percutaneous catheters (Figure 1, top) were Perifixa radiopaque polyamide catheters with an outer diameter (OD) of 0.85 mm and with three lateral openings. These catheters were inserted through an 18-gauge (OD 1.3 mm) Tuohy needle using loss of resistance technique. The catheters were fixed with adhesive dressing and attached to a 0.2-pm epidural filter (Sterifixm).
Most percutaneous catheters were not tunneled. Some were tunneled (Figure 1 , middle) for a short distance (10-30 cm). Tunneling was done either with the Tuohy needle or with a PeriplantB tunneling needle. Both the nontunneled and tunneled percutaneous catheters were inserted under local anesthesia, sometimes with intravenous sedation. Proper positioning of the catheter was confirmed by local anesthetic trial block.
We used two types of injection ports. We either implanted a PeriplanP (Figure 1, bottom) , which uses the same polyamide catheter mentioned above but with an OD of 1.05 mm, and a 16-gauge (OD 1.7 mm) Tuohy needle, or an Intraspinal Port-a-cathm. In two cases the polyurethane catheter was used with the Port-a-cathm. Plummer et al. (13) Erdine and Aldemir (18) Crul and Delhaas" (5) Hogan et al. (6) Port (6) Tunneled (15) Percutaneous (139) Tunneled (350) Percutaneous (23) Port (15) Port (313) Mixed (225) Percutaneous (95) Tunneled (15) Mixed ( In the remaining cases a Perifixa polyamide catheter (OD 1.05 mm) was used. With a few exceptions the injection ports were inserted under general anesthesia.
Proper positioning of the catheter was confirmed by iohexol (OmnipaqueB 180) contrast during fluoroscopy. During the first 2 yr of the study, we administered antibotics only to patients who had previously had an infected catheter. During the last 1% yr of the study antibiotics were administered routinely prior to implantation of injection ports. In the percutaneous group antibiotics were not administered routinely. The indication for injection ports was based primarily on life expectancy. (If a patient was believed to have a life expectancy of more than 6 wk, implantation was considered preferable.) A few patients were given subcutaneous injection ports because of repeated dislodgement of percutaneous catheters or prior infected percutaneous catheters. Some Port-a-cathsm were inserted as part of a drug trial.
During the first year of the study some of the patients were treated by intermittent injections of morphine. Later continuous infusion became the exclusive method of administration. During hospital stay, syringe drivers were used, but after discharge, patients were treated by means of portable infusion pumps (Pharmacia Deltec CADD-PCAB). The most frequently used opioid was morphine; sufentanil was used in approximately 10% of the patients. With continuous infusion, bupivacaine was added in all cases (19) . In six patients clonidine was added.
Dislodgement was recorded when the catheter tip was no longer positioned within the epidural space. In most cases the catheter was entirely outside the patient; however in a few cases, the catheter was removed after noting that the tip was located subcutaneously.
Infections were primarily infections of subcutaneous tissues. In the percutaneous catheter group this generally was characterized by purulent fluid exuding from the entry site and signs of inflammation of the surrounding skin. In the injection port group the infection site could either be at the port itself or somewhere along the trajectory between the port and the epidural space. Major infections, such as meningitis or epidural abscesses, were recorded separately.
Leakage was subdivided into several groups. In some cases, fluid coming from the catheter skin entry point was caused by edema. In some cases, there was retrograde flow of the infusion fluid along the outside of the catheter. With tunneled and implanted catheters, the fluid could exit through a fistula at the original epidural puncture site. Patients with injection ports sometimes had leakage, either at the point at which the catheter connected to the port or at which the needle became dislodged so that the analgesic solution was infused into the surrounding subcutaneous tissue. When patients with advanced cancer became emaciated and dehydrated, there was a tendency toward ulceration at the portal injection site or pressure ulcers from within at the site of the connector. Fluid could leak through these ulcers.
With intermittent administration pain on injection could occur quite suddenly; with continuous administration injection pain onset was often insidious. In our analysis we included patients who developed spinal pain at the catheter level independent of their original pain, if injection of small amounts of NaClO.9% caused pain.
Occlusion included both blockage at the distal end of the epidural catheter and kinking at any point. For the injection ports this usually occurred at the joint between the port and the catheter.
All events, including technical complications, were recorded by date. The findings were analyzed using Patfile@ software for medical statistics (Allcare, Sittard, The Netherlands). We used nonparametric tests throughout the analysis. AP-value of less than 0.05 was considered statistically significant.
Results
During the 3%-yr period from January 1,1989, to June 30, 1992, 149 patients received 250 epidural catheters (mean, 1.6 catheters per patient). This represents 0.75% of all patients seen in the Dr. Daniel den Hoed Cancer Center. Most catheters ( M = 198) were percutaneous; the remainder ( n = 52) were provided with subcutaneous injection ports. Within the former group, 41 of the 198 catheters were tunneled for short distances. The latter group included 38 PeriplantsB and 14 Port-acathsa. Thirty-two percutaneous catheters deliberately were replaced by injection ports despite the fact that they were still functioning free of complications. The two groups together represented 6969 catheter-days (4520 in the nonport group, 2449 in the port group).
The two groups were comparable with respect to age, gender, pain score (if available), and oral morphine consumption (Table 2) . We also analyzed the groups with respect to their primary tumor and found no significant differences among the groups (Table 3) . The groups were also comparable with respect to the level of the epidural catheter. For the total sample, 48% of the catheters were inserted at the lumbar level, 26% at the lower thoracic level, 22% at the upper thoracic level, and 4% at the cervical level.
Duration of Treatment
At the time of the analysis all but one patient had died. This patient's epidural catheter had been replaced by an intrathecal catheter. In 13 cases the date of discontinuation could not be traced with sufficient accuracy to include them in the analysis of duration of treatment.
The mean duration of treatment per catheter was more than twice as long ( P < 0.001) in the injection port group as in the percutaneous group (47 vs 23 days) (Table 4) . Excluding catheters deliberately replaced by injection ports did not change this difference appreciably. When considering only those catheters in which death of the patient was the reason for discontinuing treatment, the difference in duration of treatment between the groups (40 vs 34 days) was no longer significant (P = 0.09). In those cases in which a complication was the reason for discontinuing treatment the difference in duration of treatment per catheter was again highly significant (62 vs 19 days, P < 0.001). Using a Kaplan-Meier table to analyze catheter survival he., duration of treatment), we were able to apply the log-rank test. Again there was a significant difference between the two groups (P < 0.001) (Figure 2 ).
An overview of the most important technical complications is depicted graphically in Figure 3 . Figure 4 shows the same complications indexed per 1000 catheter-days. ' Failure implies failure to achieve adequate pain relief by means of epidural opioids and bupivacaine. In most of these cases pain was adequately relieved by using neurolytic techniques. Implantation refers to those catheters deliberately replaced by injection ports.
Catheter Dislodgement
None of the injection ports became dislodged. Among the percutaneous catheters, the percentage of tunneled catheters that became dislodged was as high as that of the nontunneled percutaneous catheters (22.0% vs 20.8%).
Infections
The percentage of catheters infected was roughly the same in both groups. Overall 13.6% of all catheters became infected (Figure 3) . However, when indexed per 1000 catheter-days we calculated that there were 2.86 infections/1000 catheter-days in the port group versus 5.97 infections/1000 catheter-days in the nonport group (Figure 4) .
Using a Kaplan-Meier table to consider cumulative infection rate at 7-day intervals, it became clear that injection ports, in our series, did not become infected during the first 70 days ( Figure 5 ).
Selecting only those catheters operational for less than 10 wk, the infection rate was significantly lower in the port group than in the nonport group ( P = 0.017, two-tailed Fisher's exact test).
Dividing the percutaneous catheters into a tunneled subgroup and a nontunneled subgroup revealed that tunneling alone without injection ports was associated with a higher incidence of infections (19.5% vs 12.3%), which was not statistically significant.
One patient in the percutaneous group developed clinical symptoms of meningitis, which warranted catheter removal. Cerebrospinal fluid and the catheter tip cultures revealed two different strains of bacteria.
One patient in the terminal phase of cancer developed an epidural abscess 70 days after injection port implantation. This required surgical intervention. One week later the patient became septic and died.
A third patient with an injection port developed unexplained neurologic symptoms after 133 days of treatment. Both computed tomography scan and magnetic resonance imaging suggested epidural abscess. Subsequent laminectomy revealed only infiltration without any sign of abscess. Bacterial culture was positive, but, in retrospect, could have been treated conservatively. This patient was initially free of pain after her surgical procedure; however the pain returned a few weeks later. She was later treated elsewhere by means of a bilateral cordotomy with a 1-mo interval between the two procedures. Nevertheless, she continued to suffer pain until her death approximately 6 mo later despite high-dose opioids.
Leakage
Leakage was rare in the nonport group, but took place significantly more often in the port group ( P = 0.032) (Figure 2 ). Included in this group were three cases of ulceration at the injection port site.
Pain on Injection
There was no statistical difference in the incidence of this phenomenon between the two groups ( P = 0.23) (Figure 2) .
Occlusion
Occlusion was relatively rare in the nonport group and occurred significantly more often in the port group ( P = 0.0006) (Figure 3) . This includes the kinking that took place with both of the polyurethane catheters first used with the Port-a-cathso. Later only polyamide catheters were used. 
Discussion
These results indicate that implantation of injection ports clearly prevented dislodgement. Infections occurred in as many injection ports as with percutaneous catheters, but, when indexed to catheter-days, infections occurred only half as frequently in the injection port group. If infections took place, they did so at a far later stage of treatment than with the percutaneous catheters. Leakage and occlusion, although not very common, occurred more frequently in the injection port group. Pain on injection was independent of the type of catheter. Simply tunneling the catheter did not prevent either dislodgement or infection.
As with any retrospective study, these results should be viewed with caution. For example, although the duration of treatment was significantly longer in the injection port group, we deliberately selected patients with relatively long life expectancies for implantation of injection port. In the injection port group, death was the most common cause of discontinuation of treatment; in the percutaneous group, technical complications were the most common limiting factors.
Dislodgement was a problem in the percutaneous group for the simple reason that the catheter was held in place only by the adhesive dressing. A change of dressing by an inexperienced nurse could cause the catheter to be inadvertently withdrawn from the epidural space. Tunneling the catheter to the patient's flank in itself did not prevent this; connecting it to a subcutaneous injection port made dislodgement virtually impossible. Our infection rate was higher than that of most previous studies, although several studies had similar infection rates (3,4,6,13). Our lack of dislodgements in the injection port group confirm previous findings (9) (10) (11) (12) (13) (14) (15) . Dislodgements in the tunneled group also were reported by Hogan Our method of tunneling could explain some of the difference between our findings and those of previous investigators. Most of our catheters were tunneled for only a short distance. Previous investigators (3-5) reported tunneling to the anterior or anterolateral abdominal or chest wall. DuPen et al. also reported using a catheter with a Dacron cuff that was expected to prevent both dislodgement and infection. Although they initially reported no infections in the first 55 patients (3), they later reported 53 infections in 350 patients (4).
Previous studies did not compare directly injection ports to other types of catheters. DuPen et al. (4) were the first to index the infection rate to catheter-days. We did the same for other complications. Using a survival curve, we demonstrated that infection of injection ports occurred at a far later stage than with percutaneous catheters.
We are unconvinced that prophylactic administration of antibiotics would prevent catheter infections. Although we started routinely administering antibiotics prior to implantation of injection ports in 1991, infection rates remained unchanged.
We conclude that use of injection ports for epidural administration of analgesic drugs for management of cancer pain lowers the overall complication rate when compared to percutaneous and/or tunneled catheters. We recommend their use in patients with pain due to cancer that does not respond adequately to oral or rectal opioids. We believe that only those patients with a limited life expectancy would benefit from the less invasive percutaneous catheter technique.
